Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
2 - Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
Published online by Cambridge University Press: 05 March 2016
Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Managing Myeloproliferative NeoplasmsA Case-Based Approach, pp. 9 - 16Publisher: Cambridge University PressPrint publication year: 2016
References
Vardiman, JW, Thiele, J, Arber, DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951.CrossRefGoogle ScholarPubMed
Schwaab, J, Schnittger, S, Sotlar, K, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122(14):2460–2466.CrossRefGoogle ScholarPubMed
Akin, C, Valent, P. Diagnostic criteria and classification of mastocytosis in 2014. Immunol Allergy Clin North Am. 2014;34(2):207–218.CrossRefGoogle ScholarPubMed
Zhang, LY, Smith, ML, Schultheis, B, et al. A novel K509I mutation of KIT identified in familial mastocytosis – in vitro and in vivo responsiveness to imatinib therapy. Leuk Res. 2006;30(4):373–378.CrossRefGoogle ScholarPubMed
Carter, MC, Metcalfe, DD, Komarow, HD. Mastocytosis. Immunol Allergy Clin North Am. 2014;34(1):181–196.CrossRefGoogle ScholarPubMed
Valent, P, Escribano, L, Broesby-Olsen, S, et al. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy. 2014;69(10):1267–1274.CrossRefGoogle ScholarPubMed
Bodemer, C, Hermine, O, Palmerini, F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol. 2010;130(3):804–815.CrossRefGoogle ScholarPubMed
Arock, M, Sotlar, K, Akin, C, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mactocytosis (ECNM). Leukemia. 2015; doi:10.1038/leu.2015.24.Google Scholar
Kristensen, T, Broesby-Olsen, S, Vestergaard, H, et al. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. Eur J Haematol. 2012;89(1):42–46.CrossRefGoogle ScholarPubMed
Erben, P, Schwaab, J, Metzgeroth, G, et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol. 2014;93(1):81–88.CrossRefGoogle ScholarPubMed
Schmitt-Graeff, AH, Erben, P, Schwaab, J, et al. The FIP1L1-PDGFRA fusion gene and the KIT D816V mutation are coexisting in a small subset of myeloid/lymphoid neoplasms with eosinophilia. Blood. 2014;123(4):595–597.CrossRefGoogle Scholar
Pardanani, A, Lim, KH, Lasho, TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009;114(18):3769–3772.CrossRefGoogle ScholarPubMed
Valent, P, Gleich, GJ, Reiter, A, et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol. 2012;5(2):157–176.CrossRefGoogle ScholarPubMed
Cools, J, DeAngelo, DJ, Gotlib, J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201–1214.CrossRefGoogle ScholarPubMed
Cools, J, Mentens, N, Odero, MD, et al. Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13). Blood. 2002;99(5):1776–1784.CrossRefGoogle Scholar
Metzgeroth, G, Walz, C, Erben, P, et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol. 2008;143(5):707–715.CrossRefGoogle ScholarPubMed
Baccarani, M, Cilloni, D, Rondoni, M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica. 2007;92(9):1173–1179.CrossRefGoogle ScholarPubMed
Score, J, Walz, C, Jovanovic, JV, et al. Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions. Leukemia. 2009;23(2):332–339.CrossRefGoogle ScholarPubMed
Pardanani, A, Ketterling, RP, Brockman, SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003;102(9):3093–3096.CrossRefGoogle ScholarPubMed
Jovanovic, JV, Score, J, Waghorn, K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 2007;109(11):4635–4640.CrossRefGoogle ScholarPubMed
Erben, P, Gosenca, D, Muller, MC, et al. Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica. 2010;95(5):738–744.CrossRefGoogle ScholarPubMed
Aguiar, RC, Chase, A, Coulthard, S, et al. Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement. Blood. 1997;90(8):3130–3135.CrossRefGoogle ScholarPubMed
Metzgeroth, G, Walz, C, Score, J, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia. 2007;21(6):1183–1188.CrossRefGoogle ScholarPubMed
Metzgeroth, G, Schwaab, J, Gosenca, D, et al. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia. 2013;27(11):2254–2256.CrossRefGoogle ScholarPubMed
Macdonald, D, Reiter, A, Cross, NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 2002;107(2):101–107.CrossRefGoogle ScholarPubMed
Legrand, F, Renneville, A, Macintyre, E, et al. The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases. Medicine (Baltimore). 2013; Aug 26 (epub ahead of print).CrossRefGoogle ScholarPubMed
Busque, L, Patel, JP, Figueroa, ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44(11):1179–1181.CrossRefGoogle ScholarPubMed
Maxson, JE, Gotlib, J, Pollyea, DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19):1781–1790.CrossRefGoogle ScholarPubMed
Piazza, R, Valletta, S, Winkelmann, N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013;45(1):18–24.CrossRefGoogle ScholarPubMed
Itzykson, R, Kosmider, O, Renneville, A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428–2436.CrossRefGoogle ScholarPubMed
Papaemmanuil, E, Gerstung, M, Malcovati, L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616–3627.CrossRefGoogle ScholarPubMed
Haferlach, T, Nagata, Y, Grossmann, V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241–247.CrossRefGoogle ScholarPubMed
Guglielmelli, P, Lasho, TL, Rotunno, G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014;28(9):1804–1810.CrossRefGoogle Scholar